Lexicon Genetics granted exclusive licence to Cellectis' homologous recombination technology.

(From Chemical Business NewsBase - Press Release)

Lexicon Genetics Inc (Lexicon) announced that Cellectis SA has granted Lexicon an exclusive, worldwide licence under the patents and patent applications covering Cellectis' technology for the specific replacement or insertion of a gene in a eukaryotic genome. The licence applies to the use of Cellectis' technology in combination with internal ribosome entry site (IRES) or isogenic DNA technology in the generation of genetically-modified mice. Cellectis' technology is frequently used to insert markers of gene expression or to generate mice in which the human counterpart to a mouse gene has been inserted, or "knocked …